| Literature DB >> 31832621 |
Thomas Fitzpatrick1, Weiming Tang2, Katie Mollan3, Xin Pan2, Po-Lin Chan4, Kali Zhou5, Yu Cheng6, Linghua Li7, William Cw Wong8,9, Joseph D Tucker2,10.
Abstract
BACKGROUND: Crowdsourcing may be an effective strategy to develop test promotion materials. We conducted an online randomized controlled trial (RCT) to evaluate a crowdsourced intervention to promote hepatitis B virus (HBV) and hepatitis C virus (HCV) testing among men who have sex with men (MSM) in China.Entities:
Year: 2019 PMID: 31832621 PMCID: PMC6890946 DOI: 10.1016/j.eclinm.2019.10.007
Source DB: PubMed Journal: EClinicalMedicine ISSN: 2589-5370
Fig. 1Development of images and videos to promote HBV and HCV testing through a public challenge contest. Contest implementation is presented in six stages: (1) organizing a steering committee, (2) soliciting entries, (3) promoting the contest, (4) judging entries, (5) recognizing excellent entries, and (6) sharing entries. The six stages of contest development are adapted from Wisdom of the Crowds: Methods for Organizing Crowdsourcing Challenge Contests for Health.
Fig. 2Flow diagram of enrollment, randomization, and follow-up for a nationwide online randomized controlled trial to evaluate the impact of a crowdsourced intervention on hepatitis test uptake among men who have sex with men in China, 2018.
Baseline sociodemographic characteristics, risk factors for hepatitis infection, and STI testing behaviors among 556 men enrolled in a nationwide online randomized controlled trial to evaluate the impact of a crowdsourced intervention on hepatitis test uptake among men who have sex with men in China, 2018.
| Total ( | Intervention ( | Control ( | ||||
| No. / Mean | % / SD | No. / Mean | % / SD | No. / Mean | % / SD | |
| Age | ||||||
| 25•6 | 7•0 | 25•2 | 7•0 | 25•9 | 7•0 | |
| Province | ||||||
| 103 | 18•5% | 51 | 18•2% | 52 | 18•8% | |
| 70 | 12•6% | 32 | 11•4% | 38 | 13•8% | |
| 46 | 8•3% | 24 | 8•6% | 22 | 8•0% | |
| 41 | 7•4% | 19 | 6•8% | 22 | 8•0% | |
| 296 | 53•2% | 154 | 55•0% | 142 | 51•4% | |
| Current Residence | ||||||
| 462 | 83•1% | 232 | 82•9% | 230 | 83•3% | |
| 94 | 16•9% | 48 | 17•1% | 46 | 16•7% | |
| Household Registration | ||||||
| 281 | 50•5% | 137 | 48•9% | 144 | 52•2% | |
| 275 | 49•5% | 143 | 51•1% | 132 | 47•8% | |
| Education Level | ||||||
| 128 | 23•0% | 71 | 25•4% | 57 | 20•7% | |
| 181 | 32•6% | 91 | 32•5% | 90 | 32•6% | |
| 219 | 39•4% | 107 | 38•2% | 112 | 40•6% | |
| 28 | 5•0% | 11 | 3•9% | 17 | 6•2% | |
| Occupation | ||||||
| 180 | 32•4% | 89 | 31•8% | 91 | 33•0% | |
| 123 | 22•1% | 56 | 20•0% | 67 | 24•3% | |
| 106 | 19•1% | 56 | 20•0% | 50 | 18•1% | |
| 147 | 26•4% | 79 | 28•2% | 68 | 24•6% | |
| Monthly Income (USD) | ||||||
| 149 | 26•8% | 70 | 25•0% | 79 | 28•6% | |
| 131 | 23•6% | 64 | 22•9% | 67 | 24•3% | |
| 168 | 30•2% | 89 | 31•8% | 79 | 28•6% | |
| 78 | 14•0% | 44 | 15•7% | 34 | 12•3% | |
| 30 | 5•4% | 13 | 4•6% | 17 | 6•2% | |
| Marital status | ||||||
| 485 | 87•2% | 243 | 86•8% | 242 | 87•7% | |
| 52 | 9•4% | 27 | 9•6% | 25 | 9•1% | |
| 19 | 3•4% | 10 | 3•6% | 9 | 3•3% | |
| Sexual Orientation | ||||||
| 440 | 79•1% | 216 | 77•1% | 224 | 81•2% | |
| 98 | 17•6% | 55 | 19•6% | 43 | 15•6% | |
| 4 | 0•7% | 2 | 0•7% | 2 | 0•7% | |
| 14 | 2•5% | 7 | 2•5% | 7 | 2•5% | |
| HIV status | ||||||
| 42 | 7•6% | 23 | 8•2% | 19 | 6•9% | |
| 514 | 92•4% | 257 | 91•8% | 257 | 93•1% | |
| Number male partners | ||||||
| 4•1 | 14•9 | 4•0 | 9•3 | 4•2 | 19•0 | |
| Anal sex position | ||||||
| 202 | 36•3% | 101 | 36•1% | 101 | 36•6% | |
| 106 | 19•1% | 51 | 18•2% | 55 | 19•9% | |
| 248 | 44•6% | 128 | 45•7% | 120 | 43•5% | |
| Condom use during last anal sex | ||||||
| 393 | 70•7% | 198 | 70•7% | 195 | 70•7% | |
| 163 | 29•3% | 82 | 29•3% | 81 | 29•3% | |
| Previous injection drug use | ||||||
| 15 | 2•7% | 11 | 3•9% | 4 | 1•4% | |
| 541 | 97•3% | 269 | 96•1% | 272 | 98•6% | |
| Heard of HBV previously | ||||||
| 480 | 86•3% | 236 | 84•3% | 244 | 88•4% | |
| 76 | 13•7% | 44 | 15•7% | 32 | 11•6% | |
| Heard of HCV previously | ||||||
| 351 | 63•1% | 179 | 63•9% | 172 | 62•3% | |
| 205 | 36•9% | 101 | 36•1% | 104 | 37•7% | |
| Previous HIV testing | ||||||
| 383 | 68•9% | 184 | 65•7% | 199 | 72•1% | |
| 173 | 31•1% | 96 | 34•3% | 77 | 27•9% | |
| Previous syphilis testing | ||||||
| 205 | 36•9% | 104 | 37•1% | 101 | 36•6% | |
| 351 | 63•1% | 176 | 62•9% | 175 | 63•4% | |
| Previous chlamydia testing | ||||||
| 47 | 8•5% | 24 | 8•6% | 23 | 8•3% | |
| 509 | 91•5% | 256 | 91•4% | 253 | 91•7% | |
| Previous gonorrhea testing | ||||||
| 76 | 13•7% | 36 | 12•9% | 40 | 14•5% | |
| 480 | 86•3% | 244 | 87•1% | 236 | 85•5% | |
Intention to treat analysis of primary and secondary outcomes for a nationwide online randomized controlled trial to evaluate the impact of a crowdsourced intervention on hepatitis test uptake among men who have sex with men in China, 2018.
| Total | Intervention | Control | ||||||||
| ( | ( | ( | ||||||||
| No. | % | No. | % | No. | % | OR1 | 95% CI | OR2 | 95% CI | |
| Confirmed HBV and HCV test uptake | 44 | 7•9% | 22 | 7•9% | 22 | 8•0% | 0•98 | 0•53–1•82 | 1•46 | 0•72–2•95 |
| Self-reported HBV and HCV test uptake | 97 | 17•4% | 45 | 16•1% | 52 | 18•8% | 0•82 | 0•53–1•28 | 0•94 | 0•57–1•55 |
| Confirmed HBV test uptake | 48 | 8•6% | 23 | 8•2% | 25 | 9•1% | 0•90 | 0•50–1•62 | 1•29 | 0•66–2•51 |
| Confirmed HCV test uptake | 44 | 7•9% | 22 | 7•9% | 22 | 8•0% | 0•98 | 0•53–1•82 | 1•46 | 0•72–2•95 |
| Self-reported HBV test uptake | 124 | 22•3% | 59 | 21•1% | 65 | 23•6% | 0•87 | 0•58–1•29 | 0•94 | 0•60–1•49 |
| Self-reported HCV test uptake | 103 | 18•5% | 48 | 17•1% | 55 | 19•9% | 0•83 | 0•54–1•28 | 0•96 | 0•59–1•58 |
| HBV vaccination uptake | 39 | 7•0% | 18 | 6•4% | 21 | 7•6% | 0•83 | 0•43–1•60 | 0•94 | 0•43–2•06 |
| HIV test uptake | 217 | 39•0% | 114 | 40•7% | 103 | 37•3% | 1•15 | 0•82–1•62 | 1•41 | 0•95–2•08 |
| Chlamydia test uptake | 27 | 4•9% | 14 | 5•0% | 13 | 4•7% | 1•06 | 0•49–2•31 | 1•36 | 0•62–2•96 |
| Gonorrhea test uptake | 35 | 6•3% | 17 | 6•1% | 18 | 6•5% | 0•93 | 0•47–1•84 | 1•06 | 0•51–2•20 |
| Syphilis test uptake | 116 | 20•9% | 62 | 22•1% | 54 | 19•6% | 1•17 | 0•78–1•76 | 1•44 | 0•90–2•30 |
| Visit with a physician after hepatitis test | 53 | 9•5% | 27 | 9•6% | 26 | 9•4% | 1•03 | 0•58–1•81 | 1•07 | 0•55–2•05 |
1 Odds ratios with 95% confidence intervals for intention to treat analysis using a missing=failure approach to account for men lost to follow-up.
2 Odds ratios with 95% confidence intervals for intention to treat analysis using multiple imputation to account for men lost to follow-up.
As-exposed analysis of primary and secondary outcomes for a nationwide online randomized controlled trial to evaluate the impact of a crowdsourced intervention on hepatitis test uptake among men who have sex with men in China, 2018.
| Not exposed | Partially exposed | Fully exposed | ||||||||
| ( | ( | ( | ||||||||
| No. | % | No. | % | No. | % | aOR1 | 95% CI | aOR2 | 95% CI | |
| Confirmed HBV and HCV test uptake | 22 | 8•0% | 9 | 5•5% | 13 | 10•9% | ||||
| 0•70 | 0•30–1•61 | 0•45 | 0•19–1•07 | |||||||
| 1•43 | 0•67–3•06 | 0•90 | 0•40–1•99 | |||||||
| Self-reported HBV and HCV test uptake | 30 | 10•9% | 34 | 20•9% | 33 | 27•7% | ||||
| 2•36 | 1•34–4•14 | 1•27 | 0•72–2•25 | |||||||
| 3•14 | 1•76–5•59 | 1•66 | 0•92–2•99 | |||||||
| Confirmed HBV test uptake | 25 | 9•1% | 9 | 5•5% | 14 | 11•8% | ||||
| 0•59 | 0•26–1•33 | 0•39 | 0•17–0•90 | |||||||
| 1•30 | 0•63–2•70 | 0•83 | 0•38–1•80 | |||||||
| Confirmed HCV test uptake | 22 | 8•0% | 9 | 5•5% | 13 | 10•9% | ||||
| 0•70 | 0•30–1•61 | 0•45 | 0•19–1•07 | |||||||
| 1•43 | 0•67–3•06 | 0•90 | 0•40–1•99 | |||||||
| Self-reported HBV test uptake | 40 | 14•6% | 44 | 27•0% | 40 | 33•6% | ||||
| 2•21 | 1•33–3•67 | 1•24 | 0•74–2•07 | |||||||
| 2•75 | 1•62–4•66 | 1•51 | 0•87–2•60 | |||||||
| Self-reported HCV test uptake | 32 | 11•7% | 37 | 22•7% | 34 | 28•6% | ||||
| 2•48 | 1•43–4•30 | 1•34 | 0•76–2•37 | |||||||
| 3•06 | 1•73–5•40 | 1•61 | 0•89–2•90 | |||||||
| HBV vaccination uptake | 5 | 1•8% | 16 | 9•8% | 18 | 15•1% | ||||
| 8•00 | 2•59–24•75 | 1•87 | 0•64–5•46 | |||||||
| 10•12 | 3•35–30•60 | 2•47 | 0•86–7•13 | |||||||
| HIV test uptake | 71 | 25•9% | 87 | 53•4% | 59 | 49•6% | ||||
| 3•34 | 2•19–5•12 | 1•72 | 1•10–2•69 | |||||||
| 2•72 | 1•71–4•32 | 1•40 | 0•85–2•29 | |||||||
| Chlamydia test uptake | 6 | 2•2% | 7 | 4•3% | 14 | 11•8% | ||||
| 3•04 | 0•88–10•51 | 0•70 | 0•15–3•27 | |||||||
| 7•53 | 2•46–23•04 | 2•03 | 0•61–6•77 | |||||||
| Gonorrhea test uptake | 5 | 1•8% | 15 | 9•2% | 15 | 12•6% | ||||
| 7•01 | 2•28–21•59 | 2•13 | 0•72–6•28 | |||||||
| 8•58 | 2•82–26•13 | 2•68 | 0•98–7•31 | |||||||
| Syphilis test uptake | 30 | 10•9% | 46 | 28•2% | 40 | 33•6% | ||||
| 3•57 | 2•09–6•08 | 1•85 | 1•10–3•11 | |||||||
| 4•04 | 2•31–7•06 | 2•07 | 1•19–3•59 | |||||||
| Visit with a physician after hepatitis test | 7 | 2•6% | 22 | 13•5% | 24 | 20•2% | ||||
| 7•77 | 3•01–20•09 | 2•49 | 1•07–5•82 | |||||||
| 10•18 | 4•01–25•83 | 3•25 | 1•43–7•42 | |||||||
1 Adjusted odds ratios with 95% confidence intervals for as-exposed analysis using a missing=failure approach to account for loss to follow-up. Multivariable logistic regression adjusts for age, current residence, household registration, level of education, occupation, and income.
2 Adjusted odds ratios with 95% confidence intervals for as-exposed analysis using multiple imputation to account for loss to follow-up. Multivariable logistic regression adjusts for age, current residence, household registration, level of education, occupation, and income.
3 Reference group is men not exposed to intervention materials during the four-week study period.